EA201891028A1 - Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv - Google Patents

Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv

Info

Publication number
EA201891028A1
EA201891028A1 EA201891028A EA201891028A EA201891028A1 EA 201891028 A1 EA201891028 A1 EA 201891028A1 EA 201891028 A EA201891028 A EA 201891028A EA 201891028 A EA201891028 A EA 201891028A EA 201891028 A1 EA201891028 A1 EA 201891028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trispecific
binding proteins
hiv
infection caused
prevention
Prior art date
Application number
EA201891028A
Other languages
English (en)
Russian (ru)
Inventor
Цжи-Юн Ян
Гари Дж. Нейбел
Лин СЮЙ
Ронни Вэй
Хуавэй Цю
Йохен Бенинга
Йохен Круйп
Эрколе Рао
Вульф Дирк Лойшнер
Кристиан Байль
Кристиан ЛАНГЕ
Марк Коннорс
Джон Р. Маскола
Ричард А. Кауп
Цзинхэ Хуан
Николь А. Дориа-Розе
Тунцин Чжоу
Питер Д. Квон
Йоунг До Квон
Амарендра Пегу
Мангаиаркараси Асокан
Original Assignee
Санофи
ДЗЕ ЮэсЭй, ЭЗ РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМАН СЕРВИСИЗ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи, ДЗЕ ЮэсЭй, ЭЗ РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМАН СЕРВИСИЗ filed Critical Санофи
Publication of EA201891028A1 publication Critical patent/EA201891028A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EA201891028A 2015-10-25 2016-10-24 Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv EA201891028A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Publications (1)

Publication Number Publication Date
EA201891028A1 true EA201891028A1 (ru) 2019-02-28

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891028A EA201891028A1 (ru) 2015-10-25 2016-10-24 Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv

Country Status (30)

Country Link
US (4) US20190054182A1 (enExample)
EP (2) EP3365366B1 (enExample)
JP (3) JP7169190B2 (enExample)
KR (1) KR102687212B1 (enExample)
CN (4) CN117069855A (enExample)
AR (1) AR106466A1 (enExample)
AU (2) AU2016347058B2 (enExample)
BR (1) BR112018008011A2 (enExample)
CA (1) CA3002664A1 (enExample)
CL (1) CL2018001065A1 (enExample)
CO (1) CO2018005337A2 (enExample)
CR (1) CR20180288A (enExample)
DO (1) DOP2018000102A (enExample)
EA (1) EA201891028A1 (enExample)
ES (1) ES2894304T3 (enExample)
HR (1) HRP20211528T1 (enExample)
HU (1) HUE056608T2 (enExample)
IL (2) IL301140A (enExample)
MA (1) MA42641A1 (enExample)
MX (2) MX2018005048A (enExample)
MY (1) MY192278A (enExample)
PE (1) PE20181167A1 (enExample)
PH (1) PH12018500873A1 (enExample)
PL (1) PL3365366T3 (enExample)
RS (1) RS62437B1 (enExample)
SG (1) SG11201803324VA (enExample)
SI (1) SI3365366T1 (enExample)
TW (3) TW202442675A (enExample)
UY (1) UY36965A (enExample)
WO (1) WO2017074878A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820164C2 (ru) * 2019-04-09 2024-05-30 Санофи Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP4011911A1 (en) * 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
MY192090A (en) * 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3601334A4 (en) * 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019123262A1 (en) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN111819196B (zh) * 2017-12-21 2022-10-28 纽约市哥伦比亚大学理事会 双特异性hiv-1中和抗体
IL275536B2 (en) 2018-01-12 2025-06-01 Genzyme Corp Methods for quantification of polypeptides
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
TWI856979B (zh) * 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
EP3883962A4 (en) * 2018-11-21 2023-04-12 Beth Israel Deaconess Medical Center, Inc. ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
JP7518286B2 (ja) * 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
EP4408892A4 (en) * 2021-09-29 2025-11-19 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
AU2024386429A1 (en) 2023-11-22 2026-05-21 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
AU2023474055A1 (en) 2023-11-23 2026-06-04 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025238419A1 (en) 2024-05-17 2025-11-20 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2931318A4 (en) 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN110437337B (zh) * 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TWI704229B (zh) 2015-05-20 2020-09-11 美商寬騰矽公司 核酸定序方法
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
JP6991131B2 (ja) 2015-09-22 2022-02-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法
ES2894304T3 (es) 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3575319A4 (en) 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3601334A4 (en) 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820164C2 (ru) * 2019-04-09 2024-05-30 Санофи Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv

Also Published As

Publication number Publication date
PH12018500873A1 (en) 2018-11-12
US11129905B2 (en) 2021-09-28
TW201730210A (zh) 2017-09-01
CN116675776A (zh) 2023-09-01
CA3002664A1 (en) 2017-05-04
HRP20211528T1 (hr) 2021-12-24
JP7328267B2 (ja) 2023-08-16
BR112018008011A2 (en) 2018-10-30
CN109311966B (zh) 2023-03-10
JP2018537966A (ja) 2018-12-27
WO2017074878A1 (en) 2017-05-04
JP7169190B2 (ja) 2022-11-10
CN116789841A (zh) 2023-09-22
TW202219064A (zh) 2022-05-16
AU2016347058A1 (en) 2018-06-14
EP3365366B1 (en) 2021-07-14
JP2021072847A (ja) 2021-05-13
US20220226495A1 (en) 2022-07-21
HUE056608T2 (hu) 2022-02-28
KR102687212B1 (ko) 2024-07-19
HK1253385A1 (zh) 2019-06-14
IL301140A (en) 2023-05-01
JP7724814B2 (ja) 2025-08-18
US11779651B2 (en) 2023-10-10
SI3365366T1 (sl) 2022-02-28
CN117069855A (zh) 2023-11-17
UY36965A (es) 2017-05-31
CL2018001065A1 (es) 2018-11-23
WO2017074878A8 (en) 2018-05-24
RS62437B1 (sr) 2021-11-30
KR20180063336A (ko) 2018-06-11
SG11201803324VA (en) 2018-05-30
AR106466A1 (es) 2018-01-17
CR20180288A (es) 2018-09-11
CN109311966A (zh) 2019-02-05
IL258822A (en) 2018-06-28
ES2894304T3 (es) 2022-02-14
TWI750139B (zh) 2021-12-21
IL258822B2 (en) 2023-08-01
US20200054765A1 (en) 2020-02-20
US20250312475A1 (en) 2025-10-09
NZ742825A (en) 2024-04-26
MX2022014631A (es) 2023-01-11
JP2023085476A (ja) 2023-06-20
MY192278A (en) 2022-08-16
PE20181167A1 (es) 2018-07-19
EP3365366A1 (en) 2018-08-29
MA42641A1 (fr) 2019-03-29
NZ781602A (en) 2025-07-25
PL3365366T3 (pl) 2022-01-31
AU2016347058B2 (en) 2023-11-09
EP3819310A1 (en) 2021-05-12
AU2024200395A1 (en) 2024-04-11
IL258822B1 (en) 2023-04-01
MX2018005048A (es) 2018-09-06
CO2018005337A2 (es) 2018-07-10
TW202442675A (zh) 2024-11-01
US20190054182A1 (en) 2019-02-21
DOP2018000102A (es) 2018-11-30

Similar Documents

Publication Publication Date Title
EA201892312A1 (ru) Триспецифические и/или тривалентные связывающие белки
PH12018500873A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
PH12020552229A1 (en) Il-11ra antibodies
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201991599A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
PH12018500290A1 (en) Anti-epha4 antibody
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA202092279A1 (ru) Антитела к mica и/или micb и их применение